Abstract
Understanding the mechanisms by which amyloid fibrils are formed, both in vivo and in vitro, is vital for developing methods to treat and prevent debilitating deposition diseases such as Alzheimers disease, Parkinsonas disease, type II diabetes and systemic amyloidoses. In recent years, computer modelling and biophysical studies have broadened our understanding of the biochemical mechanisms underpinning protein aggregation. As a result, it is now believed that the ability to form fibrils is an intrinsic property of polypeptide chains and not isolated to disease-related proteins or peptides. Molecular chaperones are a diverse group of functionally related proteins well known for their ability to suppress amyloid formation, and are likely to be important determinants in deciding the fate of protein aggregation prone proteins in vivo. Evidence is presented that suggests that there is striking commonality in the anti-amyloidogenic activity of molecular chaperones regardless of their structural and spatial differences. In this review, we focus on what in vitro biophysical studies tell us about amyloid formation and molecular chaperones, and how investigating the role of chaperones in fibril formation can enhance our understanding of protein misfolding diseases.
Keywords: Amyloid, protein deposition disease, chaperone, oligomer, aggregation
Current Chemical Biology
Title: Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Volume: 4 Issue: 2
Author(s): Justin J. Yerbury and Janet R. Kumita
Affiliation:
Keywords: Amyloid, protein deposition disease, chaperone, oligomer, aggregation
Abstract: Understanding the mechanisms by which amyloid fibrils are formed, both in vivo and in vitro, is vital for developing methods to treat and prevent debilitating deposition diseases such as Alzheimers disease, Parkinsonas disease, type II diabetes and systemic amyloidoses. In recent years, computer modelling and biophysical studies have broadened our understanding of the biochemical mechanisms underpinning protein aggregation. As a result, it is now believed that the ability to form fibrils is an intrinsic property of polypeptide chains and not isolated to disease-related proteins or peptides. Molecular chaperones are a diverse group of functionally related proteins well known for their ability to suppress amyloid formation, and are likely to be important determinants in deciding the fate of protein aggregation prone proteins in vivo. Evidence is presented that suggests that there is striking commonality in the anti-amyloidogenic activity of molecular chaperones regardless of their structural and spatial differences. In this review, we focus on what in vitro biophysical studies tell us about amyloid formation and molecular chaperones, and how investigating the role of chaperones in fibril formation can enhance our understanding of protein misfolding diseases.
Export Options
About this article
Cite this article as:
J. Yerbury Justin and R. Kumita Janet, Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease, Current Chemical Biology 2010; 4 (2) . https://dx.doi.org/10.2174/2212796811004020089
DOI https://dx.doi.org/10.2174/2212796811004020089 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Emerging Roles of the Unfolded Protein Response Signaling in Physiology and Disease (Executive Editor: Claudio A. Hetz and Claudio Soto )]
Current Molecular Medicine Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology One-pot Synthesis of Dihydropyrano[2,3-c]chromenes via a Three-component Reaction in Aqueous Media
Combinatorial Chemistry & High Throughput Screening The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Heat Shock Response Regulates Insulin Sensitivity and Glucose Homeostasis: Pathophysiological Impact and Therapeutic Potential
Current Diabetes Reviews Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics O-Arylation of Iodophenols with 2-Fluorobenzaldehyde Under Microwave Conditions
Letters in Drug Design & Discovery Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research The Use of Stem Cells for the Treatment of Spinal Surgical Conditions.
Current Stem Cell Research & Therapy Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design